FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597953270> ?p ?o ?g. }

• W2597953270 endingPage "1012" @default.
• W2597953270 startingPage "998" @default.
• W2597953270 abstract "A subset of renal cell carcinomas shows TFEB overexpression secondary to MALAT1-TFEB gene fusion. As alternate mechanisms of TFEB overexpression are likely to have the same effect, we sought to determine the frequency of amplification of TFEB and the adjacent VEGFA gene at 6p21.1. As patients with metastatic renal cell carcinomas are managed with anti-VEGF therapies, we retrospectively assessed therapeutic response in patients with amplified tumors. Amplification status was analyzed for 875 renal cell carcinomas from our institution, a consultative case and 794 cases from The Cancer Genome Atlas. Cases were classified as having low level (5-10 copies), and high-level amplification (>10 copies), and were further analyzed for adjacent oncogene copy number status (n=6; 3 single-nucleotide polymorphism genomic microarray, 3 The Cancer Genome Atlas) and structural rearrangements (n=1; mate-pair sequencing). These were then reviewed for histopathology, immunophenotype, and response to VEGF-targeted therapy on follow-up. In all, 10/875 (1.1%) institutional cases, 1 consultative case, and 3/794 (0.4%) of The Cancer Genome Atlas cases showed TFEB high-level amplification, while 14/875 (1.6%) cases showed TFEB low-level amplification. All cases had associated VEGFA amplification. This was confirmed with evaluation for copy number changes (n=6). The 6p21.1 high and low-level amplified tumors occurred in adults (mean age: 66), with over half being ≥pT3 (13/25, 52%), and most showed oncocytic, tubulopapillary features and high grade (≥grade 3: 20/22, 91%). These were aggressive tumors with metastasis and death from renal cell carcinoma in 11 (of 24, 46%) cases. Four patients received targeted therapy and had a mean survival of 31 months (range: 17-50) post nephrectomy. In summary, a group of aggressive renal cell carcinomas show genomic amplification of the 6p21.1 region including TFEB and VEGFA genes and share morphologic features. Additional studies are warranted to determine whether these patients respond to anti-VEGF therapy." @default.
• W2597953270 created "2017-04-07" @default.
• W2597953270 creator A5005864006 @default.
• W2597953270 creator A5021195350 @default.
• W2597953270 creator A5021419381 @default.
• W2597953270 creator A5041221293 @default.
• W2597953270 creator A5047795118 @default.
• W2597953270 creator A5051491336 @default.
• W2597953270 creator A5056909405 @default.
• W2597953270 creator A5067883322 @default.
• W2597953270 creator A5070740990 @default.
• W2597953270 creator A5073960684 @default.
• W2597953270 creator A5082725102 @default.
• W2597953270 date "2017-07-01" @default.
• W2597953270 modified "2023-10-01" @default.
• W2597953270 title "TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management" @default.
• W2597953270 cites W1540759505 @default.
• W2597953270 cites W1899682212 @default.
• W2597953270 cites W1902567769 @default.
• W2597953270 cites W1952715049 @default.
• W2597953270 cites W1971687118 @default.
• W2597953270 cites W1972836732 @default.
• W2597953270 cites W1975735776 @default.
• W2597953270 cites W1979768813 @default.
• W2597953270 cites W1985879816 @default.
• W2597953270 cites W1999094077 @default.
• W2597953270 cites W2004061241 @default.
• W2597953270 cites W2013193271 @default.
• W2597953270 cites W2015057249 @default.
• W2597953270 cites W2016972161 @default.
• W2597953270 cites W2019998985 @default.
• W2597953270 cites W2028929981 @default.
• W2597953270 cites W2032144169 @default.
• W2597953270 cites W2049407120 @default.
• W2597953270 cites W2062601645 @default.
• W2597953270 cites W2068059571 @default.
• W2597953270 cites W2069683864 @default.
• W2597953270 cites W2073342832 @default.
• W2597953270 cites W2075872896 @default.
• W2597953270 cites W2076174368 @default.
• W2597953270 cites W2078116917 @default.
• W2597953270 cites W2080073306 @default.
• W2597953270 cites W2082848670 @default.
• W2597953270 cites W2089804298 @default.
• W2597953270 cites W2093186216 @default.
• W2597953270 cites W2102442664 @default.
• W2597953270 cites W2108883548 @default.
• W2597953270 cites W2109289470 @default.
• W2597953270 cites W2110385880 @default.
• W2597953270 cites W2111070218 @default.
• W2597953270 cites W2111867681 @default.
• W2597953270 cites W2116386904 @default.
• W2597953270 cites W2116949558 @default.
• W2597953270 cites W2121203872 @default.
• W2597953270 cites W2121950946 @default.
• W2597953270 cites W2131110612 @default.
• W2597953270 cites W2132288466 @default.
• W2597953270 cites W2145902616 @default.
• W2597953270 cites W2148523790 @default.
• W2597953270 cites W2154970776 @default.
• W2597953270 cites W2167810957 @default.
• W2597953270 cites W2515985642 @default.
• W2597953270 cites W2562768756 @default.
• W2597953270 cites W321211937 @default.
• W2597953270 doi "https://doi.org/10.1038/modpathol.2017.24" @default.
• W2597953270 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28338654" @default.
• W2597953270 hasPublicationYear "2017" @default.
• W2597953270 type Work @default.
• W2597953270 sameAs 2597953270 @default.
• W2597953270 citedByCount "66" @default.
• W2597953270 countsByYear W25979532702017 @default.
• W2597953270 countsByYear W25979532702018 @default.
• W2597953270 countsByYear W25979532702019 @default.
• W2597953270 countsByYear W25979532702020 @default.
• W2597953270 countsByYear W25979532702021 @default.
• W2597953270 countsByYear W25979532702022 @default.
• W2597953270 countsByYear W25979532702023 @default.
• W2597953270 crossrefType "journal-article" @default.
• W2597953270 hasAuthorship W2597953270A5005864006 @default.
• W2597953270 hasAuthorship W2597953270A5021195350 @default.
• W2597953270 hasAuthorship W2597953270A5021419381 @default.
• W2597953270 hasAuthorship W2597953270A5041221293 @default.
• W2597953270 hasAuthorship W2597953270A5047795118 @default.
• W2597953270 hasAuthorship W2597953270A5051491336 @default.
• W2597953270 hasAuthorship W2597953270A5056909405 @default.
• W2597953270 hasAuthorship W2597953270A5067883322 @default.
• W2597953270 hasAuthorship W2597953270A5070740990 @default.
• W2597953270 hasAuthorship W2597953270A5073960684 @default.
• W2597953270 hasAuthorship W2597953270A5082725102 @default.
• W2597953270 hasBestOaLocation W25979532701 @default.
• W2597953270 hasConcept C104317684 @default.
• W2597953270 hasConcept C131934819 @default.
• W2597953270 hasConcept C132647116 @default.
• W2597953270 hasConcept C142724271 @default.
• W2597953270 hasConcept C2777472916 @default.
• W2597953270 hasConcept C2778560582 @default.
• W2597953270 hasConcept C502942594 @default.
• W2597953270 hasConcept C54355233 @default.

• next